tadalafil has been researched along with bosentan anhydrous in 34 studies
| Studies (tadalafil) | Trials (tadalafil) | Recent Studies (post-2010) (tadalafil) | Studies (bosentan anhydrous) | Trials (bosentan anhydrous) | Recent Studies (post-2010) (bosentan anhydrous) |
|---|---|---|---|---|---|
| 1,742 | 392 | 1,089 | 1,836 | 215 | 630 |
| Protein | Taxonomy | tadalafil (IC50) | bosentan anhydrous (IC50) |
|---|---|---|---|
| Endothelin receptor type B | Rattus norvegicus (Norway rat) | 0.095 | |
| Endothelin receptor type B | Homo sapiens (human) | 0.3044 | |
| Endothelin-1 receptor | Homo sapiens (human) | 0.2317 | |
| Endothelin-1 receptor | Rattus norvegicus (Norway rat) | 0.0047 | |
| Endothelin-1 receptor | Sus scrofa (pig) | 0.0075 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (5.88) | 29.6817 |
| 2010's | 27 (79.41) | 24.3611 |
| 2020's | 5 (14.71) | 2.80 |
| Authors | Studies |
|---|---|
| Dalvie, D; Loi, CM; Smith, DA | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Aisa, HA; Gong, X; He, Y; Jiang, H; Jiang, X; Li, J; Liu, Z; Shen, J; Shi, J; Suo, J; Tian, G; Wang, Y; Wang, Z; Wu, C; Wu, J; Xu, Y; Xu, Z; Yang, R; Yang, X; Zhang, R; Zhang, X; Zhu, W; Zou, X | 1 |
| Darstein, C; Dingemanse, J; Mitchell, MI; Phillips, DL; Wrishko, RE; Yu, A | 1 |
| Faruqi, S; Fathi, H; Morice, AH | 1 |
| Barst, RJ; Beardsworth, A; Brundage, BH; Chan, M; Frumkin, L; Galiè, N; Ghofrani, HA; Oudiz, RJ; Safdar, Z; Shapiro, S; Simonneau, G; White, RJ | 1 |
| Humbert, M; Jais, X; Sanchez, O; Simonneau, G; Sitbon, O | 1 |
| Barst, RJ; Beardsworth, A; Brundage, BH; Galiè, N; Ghofrani, HA; Oudiz, RJ; Simonneau, G; Sundin, DP | 1 |
| Aizawa, T; Hatano, M; Inaba, T; Kinugawa, K; Maki, H; Nagai, R; Shiga, T; Yamashita, T; Yao, A | 1 |
| Barst, RJ; Beardsworth, A; Botros, FT; Brundage, BH; Chan, M; Galiè, N; Ghofrani, HA; Oudiz, RJ; Simonneau, G | 1 |
| Burhenne, J; Haefeli, WE; Riedel, KD; Spalwisz, A; Theile, D; Weiss, J | 1 |
| El-Kersh, K; Fraig, M; Perez, RL; Smith, JS | 1 |
| Hayashi, H; Hirai, K; Itoh, K; Ono, Y; Todoroki, K; Tomatsuri, M; Toyo'oka, T; Yamada, H; Yamada, Y; Yokoyama, Y | 1 |
| Watanabe, H | 1 |
| Akita, C; Hirono, K; Ichida, F; Ishida, K; Kohno, H; Nakamura, T; Ozawa, S; Taguchi, M; Yoshimura, N | 1 |
| Baloira Villar, A; Núñez Fernández, M; Pousada Fernández, G; Valverde Pérez, D | 1 |
| Cleary, KL; Običan, SG | 1 |
| Fujita, J; Fukuda, K; Kataoka, M; Kimura, M; Kuwana, M; Ono, T; Satoh, T; Takei, M; Tamura, Y; Yamamoto, T | 1 |
| Ando, K; Hoshika, Y; Ienaga, H; Kimura, T; Kuraishi, H; Morio, Y; Nagaoka, T; Takahashi, K; Tsutsumi, T | 1 |
| Burhenne, J; Enderle, Y; Friedrich, J; Grünig, E; Haefeli, WE; Meid, AD; Wilkens, H | 1 |
| Bauer, F; Bergot, E; Bertoletti, L; Bourdin, A; Bouvaist, H; Chabannes, C; Chaouat, A; Cottin, V; Dauphin, C; De Groote, P; Humbert, M; Jaïs, X; Montani, D; Sattler, C; Savale, L; Simonneau, G; Sitbon, O | 1 |
| Azuma, H; Kajihama, A; Kajino, H; Kamiyama, N; Maeda, J; Nakau, K; Oka, H; Sugimoto, M; Tasaki, Y; Yamagishi, H | 1 |
| Jachowicz, R; Krupa, A; Majda, D; Mozgawa, W; Szlęk, J | 1 |
| Großer, C; Hoenicka, M; Hofmann, HS; Lang, G; Lehle, K; Neu, R; Ried, M; Szöke, T | 1 |
| Benjamin, N; Burhenne, J; Egenlauf, B; Enderle, Y; Fischer, C; Grünig, E; Haefeli, WE; Harutyunova, S; Huppertz, A; Klose, H; Ohnesorge, J | 1 |
| Dweik, RA; Heresi, GA; Highland, KB; Love, TE; Tonelli, AR | 1 |
| Beaussier, M; Boucau, C; Cosserat, J; Denet, C; Mascitti, P; Montandrau, O; Philip, I | 1 |
| Bonnet, D; Dahdah, N; Ferguson-Sells, L; Landry, J; Li, B; Small, D | 1 |
| Amiya, E; Asano, Y; Hatano, M; Komuro, I; Kubota, K; Maki, H; Minatsuki, S; Morita, H; Sato, S; Yoshizaki, A | 1 |
| Chen, Z; Deng, X; Li, W; Peng, Y; Wang, Y; Xiao, Y; Xiao, Z; Zeng, Y | 1 |
| Kam, CW; Ruiz, FE | 1 |
| Shi, J; Song, LL; van den Anker, J; Wu, YE; Yang, XY; Zhang, W; Zhao, W | 1 |
| Ferguson-Sells, L; Li, B; Small, D; Velez de Mendizabal, N | 1 |
6 review(s) available for tadalafil and bosentan anhydrous
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Guidelines for the diagnosis and treatment of pulmonary hypertension].
Topics: Algorithms; Antihypertensive Agents; Bosentan; Carbolines; Drug Therapy, Combination; Endothelin Receptor Antagonists; Europe; Evidence-Based Medicine; Humans; Hypertension, Pulmonary; Piperazines; Practice Guidelines as Topic; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Tadalafil; Vasodilator Agents | 2010 |
[Pharmacological treatment of pulmonary hypertension at a turning point].
Topics: Administration, Oral; Adult; Antihypertensive Agents; Bosentan; Carbolines; Endothelin Receptor Antagonists; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Infusions, Intravenous; Male; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Piperazines; Pulmonary Artery; Purines; Pyridazines; Pyrimidines; Randomized Controlled Trials as Topic; Sildenafil Citrate; Sulfonamides; Sulfones; Tadalafil; Vascular Resistance; Vasodilator Agents | 2014 |
Pulmonary arterial hypertension in pregnancy.
Topics: Anesthesia, Obstetrical; Bosentan; Carbolines; Directive Counseling; Epoprostenol; Extracorporeal Membrane Oxygenation; Familial Primary Pulmonary Hypertension; Female; Humans; Iloprost; Infant, Newborn; Piperazines; Pregnancy; Pregnancy Complications, Cardiovascular; Pregnancy Outcome; Pregnancy, High-Risk; Prognosis; Pulmonary Circulation; Purines; Sildenafil Citrate; Sulfonamides; Tadalafil | 2014 |
Opportunities and challenges of pharmacotherapy for pulmonary arterial hypertension in children.
Topics: Adolescent; Adult; Bosentan; Calcium Channel Blockers; Child; Child, Preschool; Epoprostenol; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Iloprost; Infant; Infant, Newborn; Phenotype; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Prognosis; Pulmonary Arterial Hypertension; Pyridazines; Pyrimidines; Receptors, Endothelin; Sildenafil Citrate; Sulfonamides; Tadalafil; Young Adult | 2021 |
Oral drugs used to treat persistent pulmonary hypertension of the newborn.
Topics: Administration, Oral; Antihypertensive Agents; Bosentan; Humans; Infant, Newborn; Off-Label Use; Persistent Fetal Circulation Syndrome; Randomized Controlled Trials as Topic; Sildenafil Citrate; Tadalafil | 2020 |
6 trial(s) available for tadalafil and bosentan anhydrous
| Article | Year |
|---|---|
Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects.
Topics: Administration, Oral; Adult; Antihypertensive Agents; Area Under Curve; Bosentan; Carbolines; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Interactions; Fatigue; Headache; Humans; Male; Metabolic Clearance Rate; Middle Aged; Phosphodiesterase Inhibitors; Sulfonamides; Tadalafil | 2008 |
Tadalafil therapy for pulmonary arterial hypertension.
Topics: Adult; Aged; Bosentan; Carbolines; Double-Blind Method; Endothelin Receptor Antagonists; Exercise Tolerance; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Phosphodiesterase Inhibitors; Quality of Life; Sulfonamides; Tadalafil; Treatment Outcome | 2009 |
Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Carbolines; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Sulfonamides; Tadalafil; Treatment Outcome | 2011 |
Tadalafil for the treatment of pulmonary arterial hypertension: a double-blind 52-week uncontrolled extension study.
Topics: Adult; Aged; Analysis of Variance; Antihypertensive Agents; Bosentan; Carbolines; Double-Blind Method; Drug Administration Schedule; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Prospective Studies; Sulfonamides; Tadalafil; Treatment Outcome; Vasodilator Agents | 2012 |
Pharmacokinetics and safety of tadalafil in a paediatric population with pulmonary arterial hypertension: A multiple ascending-dose study.
Topics: Adolescent; Antihypertensive Agents; Area Under Curve; Bosentan; Child; Child, Preschool; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Male; Phosphodiesterase 5 Inhibitors; Pulmonary Arterial Hypertension; Tadalafil | 2019 |
Population Pharmacokinetics of Tadalafil in Pediatric Patients with Pulmonary Arterial Hypertension: A Combined Adult/Pediatric Model.
Topics: Adult; Area Under Curve; Body Weight; Bosentan; Child; Female; Humans; Male; Pulmonary Arterial Hypertension; Tadalafil | 2022 |
22 other study(ies) available for tadalafil and bosentan anhydrous
| Article | Year |
|---|---|
Which metabolites circulate?
Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Pharmacokinetics-Driven Optimization of 4(3 H)-Pyrimidinones as Phosphodiesterase Type 5 Inhibitors Leading to TPN171, a Clinical Candidate for the Treatment of Pulmonary Arterial Hypertension.
Topics: Animals; Dogs; Drug Design; Female; Half-Life; Hypertension, Pulmonary; Male; Phosphodiesterase 5 Inhibitors; Pyrimidines; Rats; Rats, Inbred SHR; Rats, Sprague-Dawley; Sildenafil Citrate; Structure-Activity Relationship; Substrate Specificity | 2019 |
Combination of sitaxentan and tadalafil for idiopathic pulmonary arterial hypertension following relapse on bosentan.
Topics: Adult; Antihypertensive Agents; Bosentan; Carbolines; Drug Therapy, Combination; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Isoxazoles; Male; Middle Aged; Sulfonamides; Tadalafil; Thiophenes; Treatment Outcome; Vasodilator Agents | 2010 |
Initial and programmed combination therapy with oral drugs for severe idiopathic pulmonary arterial hypertension.
Topics: Administration, Oral; Antihypertensive Agents; Bosentan; Carbolines; Cardiac Output; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Echocardiography; Electrocardiography; Epoprostenol; Female; Heart Failure; Hemodynamics; Humans; Hypertension, Pulmonary; Infusions, Intravenous; Middle Aged; Sulfonamides; Tadalafil; Vasodilator Agents | 2011 |
Influence of sildenafil and tadalafil on the enzyme- and transporter-inducing effects of bosentan and ambrisentan in LS180 cells.
Topics: Antihypertensive Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Bosentan; Carbolines; Cell Line, Tumor; Cytochrome P-450 CYP3A; Drug Interactions; Endothelin A Receptor Antagonists; Gene Expression Regulation; Genes, Reporter; Humans; Intestinal Absorption; Intestinal Mucosa; Intestines; Peroxisome-Targeting Signal 1 Receptor; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Piperazines; Pregnane X Receptor; Promoter Regions, Genetic; Purines; Pyridazines; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; Recombinant Proteins; RNA, Messenger; Sildenafil Citrate; Sulfonamides; Sulfones; Tadalafil | 2013 |
Smoking-related interstitial fibrosis (SRIF) and pulmonary hypertension.
Topics: Antihypertensive Agents; Biopsy; Bosentan; Carbolines; Cardiac Catheterization; Drug Therapy, Combination; Humans; Hypertension, Pulmonary; Male; Middle Aged; Pulmonary Fibrosis; Respiratory Function Tests; Smoking; Sulfonamides; Tadalafil; Tomography, X-Ray Computed; Vasodilator Agents | 2013 |
Simultaneous microdetermination of bosentan, ambrisentan, sildenafil, and tadalafil in plasma using liquid chromatography/tandem mass spectrometry for pediatric patients with pulmonary arterial hypertension.
Topics: Bosentan; Carbolines; Child; Child, Preschool; Chromatography, Liquid; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Infant; Male; Phenylpropionates; Piperazines; Purines; Pyridazines; Sildenafil Citrate; Sulfonamides; Sulfones; Tadalafil; Tandem Mass Spectrometry | 2014 |
Plasma concentrations of tadalafil in children with pulmonary arterial hypertension.
Topics: Adolescent; Aging; Antihypertensive Agents; Bosentan; Carbolines; Child; Child, Preschool; Female; Humans; Hypertension, Pulmonary; Infant; Male; Sulfonamides; Tadalafil; Vasodilator Agents | 2014 |
Clinical and molecular study of 4 cases of pulmonary hypertension associated with sarcoidosis.
Topics: Bone Morphogenetic Protein Receptors, Type II; Bosentan; Disease Progression; Epoprostenol; Fatal Outcome; Female; Humans; Hypertension, Pulmonary; Kv1.5 Potassium Channel; Male; Middle Aged; Mutation; Phenylpropionates; Point Mutation; Pyridazines; Respiratory Function Tests; RNA, Messenger; Sarcoidosis; Sildenafil Citrate; Sulfonamides; Tadalafil; Treatment Outcome | 2015 |
Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study.
Topics: Adult; Antihypertensive Agents; Bosentan; Cardiac Catheterization; Drug Therapy, Combination; Endothelin Receptor Antagonists; Epoprostenol; Exercise Test; Female; Humans; Hypertension, Pulmonary; Middle Aged; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Pilot Projects; Prostaglandins; Pulmonary Wedge Pressure; Pyridazines; Retrospective Studies; Sildenafil Citrate; Sulfonamides; Tadalafil; Treatment Outcome; Vascular Resistance; Young Adult | 2015 |
Potential Role of CT Metrics in Chronic Obstructive Pulmonary Disease with Pulmonary Hypertension.
Topics: Aged; Bosentan; Endothelin Receptor Antagonists; Exercise Test; Female; Forced Expiratory Volume; Humans; Hypertension, Pulmonary; Male; Middle Aged; Pulmonary Artery; Pulmonary Diffusing Capacity; Pulmonary Disease, Chronic Obstructive; Pulmonary Fibrosis; Sildenafil Citrate; Sulfonamides; Tadalafil; Tomography, X-Ray Computed; Vasodilator Agents; Vital Capacity | 2015 |
Dried Blood Spot Technique for the Monitoring of Ambrisentan, Bosentan, Sildenafil, and Tadalafil in Patients with Pulmonary Arterial Hypertension.
Topics: Bosentan; Chromatography, Liquid; Dried Blood Spot Testing; Humans; Hypertension, Pulmonary; Limit of Detection; Phenylpropionates; Pyridazines; Reproducibility of Results; Sildenafil Citrate; Sulfonamides; Tadalafil; Tandem Mass Spectrometry | 2015 |
Initial dual oral combination therapy in pulmonary arterial hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Diethylpropion; Drug Therapy, Combination; Familial Primary Pulmonary Hypertension; Female; Follow-Up Studies; Hemodynamics; Humans; Hypertension, Pulmonary; Male; Middle Aged; Patient Safety; Phenylpropionates; Pyridazines; Retrospective Studies; Severity of Illness Index; Sildenafil Citrate; Sulfonamides; Tadalafil; Time Factors; Treatment Outcome | 2016 |
Pharmacokinetics of drugs for pediatric pulmonary hypertension.
Topics: Administration, Oral; Adolescent; Antihypertensive Agents; Bosentan; Child; Child, Preschool; Chromatography, High Pressure Liquid; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Infant; Male; Phosphodiesterase 5 Inhibitors; Prospective Studies; Pulmonary Wedge Pressure; Sulfonamides; Tadalafil; Young Adult | 2016 |
Physicochemical Properties of Bosentan and Selected PDE-5 Inhibitors in the Design of Drugs for Rare Diseases.
Topics: Bosentan; Drug Design; Humans; Hypertension, Pulmonary; Phosphodiesterase 5 Inhibitors; Rare Diseases; Sildenafil Citrate; Sulfonamides; Tadalafil | 2017 |
Superior vasodilation of human pulmonary vessels by vardenafil compared with tadalafil and sildenafil: additive effects of bosentan.
Topics: Antihypertensive Agents; Bosentan; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Pulmonary Artery; Pulmonary Veins; Sildenafil Citrate; Sulfonamides; Tadalafil; Vardenafil Dihydrochloride; Vasodilation; Vasodilator Agents | 2017 |
Plasma Drug Concentrations in Patients with Pulmonary Arterial Hypertension on Combination Treatment.
Topics: Adult; Aged; Bosentan; Case-Control Studies; Drug Interactions; Drug Therapy, Combination; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Pyridazines; Pyrimidines; Sildenafil Citrate; Sulfonamides; Tadalafil | 2017 |
Choice of Initial Oral Therapy for Pulmonary Arterial Hypertension: Age and Long-Term Survival.
Topics: Administration, Oral; Age Factors; Bosentan; Drug Therapy, Combination; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Pyridazines; Pyrimidines; Retrospective Studies; Sildenafil Citrate; Sulfonamides; Tadalafil | 2018 |
Laparoscopic Rectopexy in a Patient With Pulmonary Hypertension Associated With Scleroderma: A Case Report.
Topics: Aged; Antihypertensive Agents; Bosentan; Female; Head-Down Tilt; Humans; Hypertension, Pulmonary; Laparoscopy; Preoperative Care; Rectal Prolapse; Tadalafil; Treatment Outcome | 2019 |
Characteristics of Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis and Anticentriole Autoantibodies.
Topics: Aged; Aged, 80 and over; Antibodies, Antinuclear; Autoantibodies; Bosentan; Cardiac Catheterization; Centrioles; Drug Therapy, Combination; Endothelin Receptor Antagonists; Epoprostenol; Female; Forced Expiratory Volume; Humans; Imatinib Mesylate; Protein Kinase Inhibitors; Pulmonary Arterial Hypertension; Pulmonary Diffusing Capacity; Pyrimidines; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Tadalafil; Tomography, X-Ray Computed; Vasodilator Agents | 2020 |
Ligation of patent ductus venosus in a child with pulmonary arterial hypertension and hypersplenism: A case report.
Topics: Aftercare; Antihypertensive Agents; Bosentan; Cardiomegaly; Child, Preschool; Combined Modality Therapy; Echocardiography; Humans; Hypersplenism; Ligation; Male; Portal Vein; Pulmonary Arterial Hypertension; Radiography, Thoracic; Tadalafil; Tomography, X-Ray Computed; Treatment Outcome; Vascular Malformations; Vascular Resistance; Vasodilator Agents | 2020 |